Hydropothecary (TSX VENTURE: $THCX.V) Announces Release Of Honeydew, One Of Canada's Highest Legal CBD:THC Ratio Products To Date
GATINEAU, QC - August 15, 2017 (Investorideas.com Newswire) The Hydropothecary Corporation (TSX VENTURE: THCX) (the "Company" or "Hydropothecary") is pleased to announce it has started shipping Honeydew, the Company's highest CBD:THC ratio product offering to date.
Part of the Company's mid-market H2 product line, the dried bud has a ratio of 18.5 percent CBD to 1.8 percent THC, making it one of the highest CBD products available under Health Canada's regulations.
Honeydew complements the Company's existing CBD offerings, and brings the Company's total number of CBD products to five, including the recently released Passion Fruit. Passion Fruit is an indica-dominant hybrid cannabis strain that offers a 1:2 ratio of 5.1 percent THC to 10.7 percent CBD. Rounding out the CBD offering is Midday, Decarb 1:1 and Decarb High CBD.
"Together with our other H2 products, including Passion Fruit, Papaya Grove, Dragon Fruit, Bitter Melon and Juniper Berry, Honeydew has been developed to meet the needs of our clients at affordable prices, starting at just $7.25/g. Every new product we roll out has been carefully developed in response to what health care professionals need to help their patients," says Sebastien St-Louis, CEO and co-founder.
Honeydew and Passion Fruit are both available for $10/g under the H2 product line. For more information, please visit www.thehydropothecary.com/products/h2.
About The Hydropothecary Corporation
Hydropothecary is an authorized licensed producer and distributor of medical cannabis licensed by Health Canada under the Access to Cannabis for Medical Purposes Regulations (Canada). Hydropothecary provides naturally grown and rigorously tested medical cannabis of uncompromising quality. Hydropothecary's branding, cannabis product offering, patient service standards and product pricing are consistent with Hydropothecary's positioning as a premium brand for a legal source for medical cannabis within this new marketplace. In addition to medical cannabis production and sales, Hydropothecary explores various research and development opportunities for cannabinoid extracts, drugs and combinatory chemistry. In addition, the company is investigating the development and patenting of novel technologies related to medical cannabis, as well as the import and export of medical cannabis.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
For further information, please contact:
Manager of Financial Reporting and Investor Relations
Like Marijuana Stocks? View our Marijuana / Hemp Stocks Directory
Join our Group on Linkedin - Marijuana / Hemp Stocks - News and Trends in Green Investing
Watch the 420 Cannabis Investor video
This news is published on the Investorideas.com Newswire - a global digital news source for investors and business leaders
Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release on the Investorideas.com newswire https://www.investorideas.com/News-Upload/
Additional info regarding BC Residents and global Investors: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: https://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.